An EU manufacturer cannot hold a Malaysian registration directly - you need a locally incorporated Marketing Authorisation Holder (MAH). Because the EMA is a recognised reference agency, your approval opens NPRA's Facilitated Registration Pathway - for most manufacturers the abbreviated review at 90 working days (filed within three years). A narrower pilot targets 60 working days, but only for an EMA centralised approval filed within about three months and left unchanged - a window most products miss. Swissmedic and UK MHRA approvals are also recognised.
A note on terms: NPRA officially calls the holder the Product Registration Holder (PRH). Throughout RHMI's guides we use the equivalent international term, Marketing Authorisation Holder (MAH) - they mean the same party.
If you hold an EMA, Swissmedic or UK MHRA marketing authorisation, Malaysia is one of the few Asian markets where that approval does measurable work for you. Three of NPRA's seven recognised reference agencies are European - EMA, Swissmedic and the UK MHRA - so a European approval opens a reliance route that shortens the review.
How fast can an EMA-approved drug be registered?
For most European manufacturers the realistic route is the general Facilitated Registration Pathway: abbreviated review at 90 working days, or verification review at 30 working days, filed within three years of the reference approval. This is the route to plan around - it applies to EMA, Swissmedic and UK MHRA approvals alike.
A separate, faster pilot exists, but it is narrow. Since 2 May 2026 NPRA has run a one-year pilot targeting 60 working days - and most European products will not fit it, because the conditions are strict:
- Approval by EMA through the centralised procedure, or the decentralised procedure limited to generic products - national and mutual-recognition approvals do not qualify.
- Filed within about three months of the reference approval date - a window most manufacturers miss, because Malaysia is rarely the next market on the list.
- The product must be identical to the approved one: same active ingredients, strength, dosage form, route of administration, indications, formulation and container closure system.
- All manufacturing and testing sites must match those approved by EMA.
- Maximum three rounds of correspondence; products approved under exceptional circumstances are excluded.
So treat the 60-working-day pilot as a best case for a narrow set of EMA centralised products, and the 90-working-day abbreviated route as the realistic plan for everyone else. The full fast-track rules are here.
Do you need a Malaysian entity? Three structures compared
You cannot hold the registration yourself. That is not negotiable, and it is the single fact that shapes every European entry into Malaysia.
| Structure | Control | Speed to market | Cost | Exit risk |
|---|---|---|---|---|
| Distributor holds the registration | Low | Fast | Low | High |
| Your own Malaysian subsidiary | Full | Slow | High | Low |
| Independent MAH (RHMI) | High | Fast | Medium | Low |
| Licensing the product out | None | Fast | None | Total - it is no longer your market |
The lock-in question no one raises until it is too late
The convenient path is to let your Malaysian distributor take the holder role. It costs nothing up front and it is faster. It also means that if the commercial relationship sours, the registration - your route to the market - is in your former partner's name, and moving it requires their consent. This is the lock-in risk in detail, and this is how a transfer works if you are already in that position.
From EU-CTD to ACTD: what actually changes
Malaysia uses the ASEAN Common Technical Document (ACTD), not the ICH CTD you filed with EMA. The science does not change; the packaging does. Broadly, your EU Module 3 quality data maps into ACTD Part II, non-clinical into Part III and clinical into Part IV, with Part I carrying the administrative and product information - including Malaysian labelling requirements that have no EU equivalent. Most of the dossier is reusable. What is not: local labelling, certain site documentation, and a Certificate of Pharmaceutical Product.
PIC/S and your EU GMP status
Malaysia is a PIC/S member and so are the EU member states. In practice this means an EU-inspected manufacturing site starts from a position of recognition rather than suspicion. It does not mean your GMP certificate is a passport - NPRA still assesses site documentation, and requirements differ by product type. But for an EU manufacturer this is one of the lower hurdles in the process.
Timeline and cost, honestly
Registration is the long pole. Beyond the review clock itself, the realistic schedule depends on dossier readiness and how quickly you answer NPRA queries - applicants typically have a limited window to respond, and slow responses are a frequent cause of delay. After the MAL number is issued you still need an import licence and GDP-compliant distribution before the first sale. The full process and requirements are here, and licensing and GDP are covered here.
After registration: who carries the obligations
The holder is on the hook, continuously: pharmacovigilance, variations, renewals, recalls, and - since 1 July 2026 - mandatory reporting of medicine shortages and discontinuations. If your distributor is the holder, your distributor owns those obligations and the relationship with the regulator. If an independent MAH holds them, you keep the regulatory relationship separate from the commercial one. What an MAH actually does.
Why Malaysia at all
For a mid-size European manufacturer the case is not market size - it is that Malaysia is an English-language PIC/S market with reliance routes, and a workable base for the wider ASEAN region. The full case for Malaysia as an EU entry point.
Frequently asked questions
Can a European manufacturer hold a drug registration in Malaysia?
No. The holder must be a locally incorporated Malaysian entity. An EU manufacturer appoints a local Marketing Authorisation Holder - which may be its distributor, its own subsidiary, or an independent MAH that is not its commercial partner.
Does an EMA approval fast-track registration in Malaysia?
Yes, in two ways. An EMA centralised approval can qualify for a pilot route targeting 60 working days, if filed within about three months of approval and the product is identical to the approved version. Otherwise the general Facilitated Registration Pathway offers abbreviated review at 90 working days or verification review at 30 working days, filed within three years.
Are Swissmedic and UK MHRA approvals recognised in Malaysia?
Yes. Both are among NPRA's seven recognised reference agencies for the general Facilitated Registration Pathway. Neither is included in the 60-working-day pilot, which accepts only EMA and US FDA approvals.
Do I have to convert my EU CTD dossier to ACTD?
Yes. Malaysia uses the ASEAN Common Technical Document. Most of the scientific content of an EU dossier is reusable, but it is reorganised into ACTD Parts I to IV, and Malaysian-specific items such as local labelling and a Certificate of Pharmaceutical Product must be added.
You might also find useful
- Fast-Track Registration: Register Your FDA/EMA-Approved Drug Faster in Malaysia
- Why Malaysia: Market Entry for EU Pharma
- Marketing Authorisation Holder (MAH) in Malaysia: What It Is and How to Appoint One
- Sources:
- NPRA - New Route under the Facilitated Registration Pathway (FRP), one-year pilot from 2 May 2026: npra.gov.my
- NPRA Drug Registration Guidance Document (DRGD): npra.gov.my (DRGD)
- RAPS - Malaysia's NPRA updates regulatory reliance guide, expands pool of reference agencies: raps.org
- Editorial note: This page is general business and regulatory information for manufacturers evaluating Malaysia. It is not legal or regulatory advice. Timelines, fees and eligibility are administrative details that change; confirm them against NPRA's current guidance before acting. Last reviewed against NPRA guidance: 15 August 2026.